Managing Director, Equity Research – Life Science Tools & Diagnostics J.P. Morgan
The pandemic has clearly highlighted the value of diagnostics for patient and public health. Since the start of the pandemic, private and public investors have rapidly augmented resources in the diagnostics space for laboratory and point-of-care solutions. Panelists will discuss the response of the investor community to the pandemic as well as the critical role of government and NGO investment in diagnostics globally, including the role of the World Health Organization Access to COVID-19 Tools (ACT) Accelerator. Panelists will reflect on how, despite the essential role of diagnostics in ongoing response efforts, global investments in diagnostics have lagged those made for therapeutics and vaccines. The implications are felt particularly by low- and middle-income countries (LMICs), many of which have struggled to access diagnostic tests, thus affecting their ability to effectively manage the ongoing COVID-19 pandemic. Finally, this session will explore the most promising opportunities for investment moving forward.